Biochemical markers of ongoing joint damage in rheumatoid arthritis - current and future applications, limitations and opportunities

[1]  M. Karsdal,et al.  Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM--increased serum CIIM in subjects with severe radiographic osteoarthritis. , 2011, Clinical biochemistry.

[2]  M. Weisman,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 , 2011, Annals of the rheumatic diseases.

[3]  M. Karsdal,et al.  Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease? , 2010, Clinical biochemistry.

[4]  D. M. van der Heijde,et al.  Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study , 2010, Modern rheumatology.

[5]  Gerhard Hawa,et al.  Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. , 2010, The Journal of clinical endocrinology and metabolism.

[6]  M. Karsdal,et al.  Should biochemical markers of bone turnover be considered standard practice for safety pharmacology? , 2010, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[7]  D. M. van der Heijde,et al.  Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs , 2010, Annals of the rheumatic diseases.

[8]  Kim Henriksen,et al.  Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis? , 2010, Rheumatology International.

[9]  M. Karsdal,et al.  Application of biochemical markers in development of drugs for treatment of osteoarthritis , 2010, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[10]  D. Fernández-García,et al.  Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate. , 2009, Maturitas.

[11]  B. Dijkmans,et al.  Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. , 2009, Arthritis and rheumatism.

[12]  P. Garnero,et al.  Opposite relationships between circulating Dkk-1 and cartilage breakdown in patients with rheumatoid arthritis and knee osteoarthritis , 2009, Annals of the rheumatic diseases.

[13]  Y. Kadono,et al.  Rheumatoid arthritis associated with osteopetrosis , 2009, Modern rheumatology.

[14]  V. Everts,et al.  Osteoclast heterogeneity: lessons from osteopetrosis and inflammatory conditions. , 2009, Biochimica et biophysica acta.

[15]  Olga Kubassova,et al.  MRI quantification of rheumatoid arthritis: current knowledge and future perspectives. , 2009, European journal of radiology.

[16]  B. Lie,et al.  Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study , 2009, Annals of the rheumatic diseases.

[17]  Mads Nielsen,et al.  Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers , 2009, Arthritis research & therapy.

[18]  S. Teitelbaum,et al.  Osteoclasts and Arthritis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  M. Uetani,et al.  High Serum Cartilage Oligomeric Matrix Protein Determines the Subset of Patients with Early-Stage Rheumatoid Arthritis with High Serum C-Reactive Protein, Matrix Metalloproteinase-3, and MRI-Proven Bone Erosion , 2009, The Journal of Rheumatology.

[20]  M. Goldring,et al.  Cartilage homeostasis in health and rheumatic diseases , 2009, Arthritis research & therapy.

[21]  Kazuhiko Yamamoto,et al.  A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs , 2009, Modern rheumatology.

[22]  M. Karsdal,et al.  Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[23]  D. Eyre,et al.  The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence. , 2009, Osteoarthritis and cartilage.

[24]  M. Karsdal,et al.  Influence of food intake on the bioavailability and efficacy of oral calcitonin. , 2009, British Journal of Clinical Pharmacology.

[25]  M. Karsdal,et al.  Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. , 2009, Osteoarthritis and cartilage.

[26]  P. Junker,et al.  Differential association of the N-propeptide of collagen IIA (PIIANP) and collagen II C-telopeptide (CTX-II) with synovitis and erosions in early and longstanding rheumatoid arthritis. , 2009, Clinical and experimental rheumatology.

[27]  D. M. van der Heijde,et al.  Cartilage and Bone Biomarkers in Rheumatoid Arthritis: Prediction of 10-year Radiographic Progression , 2009, The Journal of Rheumatology.

[28]  G. Schett,et al.  Bone Marrow Edema , 2009, Annals of the New York Academy of Sciences.

[29]  G. Schett.  Osteoimmunology in rheumatic diseases , 2009, Arthritis research & therapy.

[30]  J. Smolen,et al.  Developments in the clinical understanding of rheumatoid arthritis , 2009, Arthritis research & therapy.

[31]  C. Christiansen,et al.  Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin , 2008, BMC clinical pharmacology.

[32]  M. Hellio le Graverand,et al.  Discovery and development of the N-terminal procollagen type II (NPII) biomarker: a tool for measuring collagen type II synthesis. , 2008, Osteoarthritis and cartilage.

[33]  V. Kraus,et al.  Variation in osteoarthritis biomarkers from activity not food consumption. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[34]  J. Risteli,et al.  Erosive arthritis in a patient with pycnodysostosis: an experiment of nature. , 2008, Arthritis and rheumatism.

[35]  P. Garnero,et al.  PIIANP and HELIXII diurnal variation. , 2008, Osteoarthritis and cartilage.

[36]  P. Rahman,et al.  Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. , 2008, The Journal of rheumatology.

[37]  O. Nemirovskiy,et al.  Immunoaffinity liquid chromatography-tandem mass spectrometry detection of nitrotyrosine in biological fluids: development of a clinically translatable biomarker. , 2008, Analytical biochemistry.

[38]  P. Delmas,et al.  Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[39]  S. van der Linden,et al.  Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. , 2008, Rheumatology.

[40]  D. Neustadt,et al.  Significance of Serum TRACP in Rheumatoid Arthritis , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  Mikkel Ostergaard,et al.  Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome. , 2008, The Journal of rheumatology.

[42]  C. Christiansen,et al.  Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. , 2008, Osteoarthritis and cartilage.

[43]  K Henriksen,et al.  Should subchondral bone turnover be targeted when treating osteoarthritis? , 2008, Osteoarthritis and cartilage.

[44]  B. Dijkmans,et al.  Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis--data from the RAPIT study. , 2008, Rheumatology.

[45]  M. Karsdal,et al.  Patients with rheumatoid arthritis have an altered circulatory aggrecan profile , 2008, BMC musculoskeletal disorders.

[46]  E. Vignon,et al.  Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis. , 2008, Clinical and experimental rheumatology.

[47]  Y. Allanore,et al.  Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs , 2008, Expert opinion on pharmacotherapy.

[48]  George Kollias,et al.  Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice. , 2008, Arthritis and rheumatism.

[49]  J. Rissanen,et al.  Secreted Tartrate-Resistant Acid Phosphatase 5b is a Marker of Osteoclast Number in Human Osteoclast Cultures and the Rat Ovariectomy Model , 2008, Calcified Tissue International.

[50]  P. Hannonen,et al.  Combination drug strategy in recent‐onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression , 2008, Scandinavian journal of rheumatology.

[51]  Claus Christiansen,et al.  Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity , 2008, Arthritis research & therapy.

[52]  R. Landewé.  Predictive markers in rapidly progressing rheumatoid arthritis. , 2007, The Journal of rheumatology. Supplement.

[53]  H. Yamanaka,et al.  Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA , 2007, Modern rheumatology.

[54]  B. Bresnihan,et al.  Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. , 2007, Arthritis and rheumatism.

[55]  P. Garnero,et al.  Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[56]  M. Bala,et al.  Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. , 2007, The Journal of rheumatology.

[57]  G. Schett.  Erosive arthritis , 2007, Arthritis research & therapy.

[58]  A. Bailey,et al.  Bone, not cartilage, should be the major focus in osteoarthritis , 2007, Nature Clinical Practice Rheumatology.

[59]  M. Dougados,et al.  Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. , 2007, Arthritis and rheumatism.

[60]  M. Karsdal,et al.  Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. , 2007, Arthritis and rheumatism.

[61]  W. Maksymowych,et al.  Validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging spinal inflammation index: is it necessary to score the entire spine? , 2007, Arthritis and rheumatism.

[62]  Claus Christiansen,et al.  Are Nonresorbing Osteoclasts Sources of Bone Anabolic Activity? , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[63]  Claus Christiansen,et al.  Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases , 2007, Osteoporosis International.

[64]  M. Karsdal,et al.  Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. , 2007, Osteoarthritis and cartilage.

[65]  P. Geusens,et al.  Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials. , 2007, The Journal of rheumatology.

[66]  M. Karsdal,et al.  MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. , 2007, Osteoarthritis and cartilage.

[67]  O. Nemirovskiy,et al.  Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo. , 2007, Analytical biochemistry.

[68]  Georg Schett,et al.  Dickkopf-1 is a master regulator of joint remodeling , 2007, Nature Medicine.

[69]  M. Karsdal,et al.  Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood , 2006, Journal of Bone and Mineral Metabolism.

[70]  E. Roos,et al.  Serum levels of Cartilage Oligomeric Matrix Protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis , 2006, BMC musculoskeletal disorders.

[71]  M. Hansen,et al.  Osteosarcoma in Paget's Disease of Bone , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[72]  F. Breedveld,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011 , 2006, Annals of the rheumatic diseases.

[73]  R. Buck,et al.  Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. , 2006, Osteoarthritis and cartilage.

[74]  T. Spector,et al.  Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. , 2006, Arthritis and rheumatism.

[75]  L. Tankó,et al.  Early elevation in circulating levels of C-telopeptides of type II collagen predicts structural damage in articular cartilage in the rodent model of collagen-induced arthritis. , 2006, Arthritis and rheumatism.

[76]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[77]  M. Karsdal,et al.  An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice , 2006, European Journal of Clinical Pharmacology.

[78]  M. Karsdal,et al.  Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. , 2006, Osteoarthritis and cartilage.

[79]  J. Jordan,et al.  Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. , 2006, Arthritis and rheumatism.

[80]  Claus Christiansen,et al.  Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. , 2006, Arthritis and rheumatism.

[81]  D J Hunter,et al.  Classification of osteoarthritis biomarkers: a proposed approach. , 2006, Osteoarthritis and cartilage.

[82]  M. Karsdal,et al.  Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. , 2006, Osteoarthritis and cartilage.

[83]  M. Karsdal,et al.  Alpha CTX as a Biomarker of Skeletal Invasion of Breast Cancer: Immunolocalization and the Load Dependency of Urinary Excretion , 2006, Cancer Epidemiology Biomarkers & Prevention.

[84]  S. Kumar,et al.  Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. , 2006, Osteoarthritis and cartilage.

[85]  M. Karsdal,et al.  The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. , 2006, Osteoarthritis and cartilage.

[86]  P. Delmas,et al.  Bone quality--the material and structural basis of bone strength and fragility. , 2006, The New England journal of medicine.

[87]  B. Månsson,et al.  Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[88]  John Han,et al.  Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. , 2006, Arthritis and rheumatism.

[89]  P. Miller,et al.  Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2007 .

[90]  M. Abrahamowicz,et al.  Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis , 2006, Arthritis Research & Therapy.

[91]  L. Tankó,et al.  The Relative Use of Eight Collagenous and Noncollagenous Markers for Diagnosis of Skeletal Metastases in Breast, Prostate, or Lung Cancer Patients , 2006, Cancer Epidemiology Biomarkers & Prevention.

[92]  L. Tankó,et al.  Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review , 2006, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[93]  M. Dougados,et al.  Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH* Cohort , 2005, Annals of the rheumatic diseases.

[94]  E. Vuorio,et al.  Spontaneous development of synovitis and cartilage degeneration in transgenic mice overexpressing cathepsin K. , 2005, Arthritis and rheumatism.

[95]  M. Karsdal,et al.  In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? , 2005, Assay and drug development technologies.

[96]  J. Zwerina,et al.  Mechanisms of Disease: the link between RANKL and arthritic bone disease , 2005, Nature Clinical Practice Rheumatology.

[97]  T. Lehtimäki,et al.  Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[98]  M. Stolina,et al.  Analysis of the kinetics of osteoclastogenesis in arthritic rats. , 2005, Arthritis and rheumatism.

[99]  John C. Davis,et al.  Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. , 2005, The Journal of rheumatology.

[100]  M. Karsdal,et al.  Degradation of the Organic Phase of Bone by Osteoclasts: A Secondary Role for Lysosomal Acidification , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[101]  C. Peterfy,et al.  Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. , 2005, Arthritis and rheumatism.

[102]  C. Pieper,et al.  Variation of serum hyaluronan with activity in individuals with knee osteoarthritis. , 2005, Osteoarthritis and cartilage.

[103]  G. Schett,et al.  New insights in the mechanism of bone loss in arthritis. , 2005, Current pharmaceutical design.

[104]  S. van der Linden,et al.  Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis , 2005, Annals of the rheumatic diseases.

[105]  D. Brömme,et al.  The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. , 2005, Advanced drug delivery reviews.

[106]  P. Garnero,et al.  Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. , 2005, Arthritis and rheumatism.

[107]  M. Dougados,et al.  Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. , 2005, The Journal of rheumatology.

[108]  H. Ma,et al.  Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis , 2005, Nature.

[109]  A. Fourie,et al.  ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro , 2005, Nature.

[110]  M. Stone,et al.  Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response. , 2005, Arthritis and rheumatism.

[111]  R. Bräuer,et al.  Local expression of matrix metalloproteinases, cathepsins, and their inhibitors during the development of murine antigen-induced arthritis , 2004, Arthritis research & therapy.

[112]  A. Poole,et al.  The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. , 2004, Journal of immunological methods.

[113]  L. Hofbauer,et al.  Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. , 2004, The Journal of rheumatology.

[114]  Hanwei Zhang,et al.  Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. , 2004, Arthritis and rheumatism.

[115]  D. Baeten,et al.  Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. , 2004, Arthritis and rheumatism.

[116]  C. Christiansen,et al.  Safety and Efficacy of a Novel Salmon Calcitonin (sCT) Technology‐Based Oral Formulation in Healthy Postmenopausal Women: Acute and 3‐Month Effects on Biomarkers of Bone Turnover , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[117]  M. Dougados,et al.  What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. , 2004, Arthritis and rheumatism.

[118]  A. Uitterlinden,et al.  A new marker for osteoarthritis: cross-sectional and longitudinal approach. , 2004, Arthritis and rheumatism.

[119]  E. Vignon,et al.  Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. , 2004, Osteoarthritis and cartilage.

[120]  E. Vuorio,et al.  Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis , 2004, Annals of the rheumatic diseases.

[121]  S. van der Linden,et al.  Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[122]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[123]  L. Klareskog,et al.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.

[124]  P. Lipsky,et al.  Infliximab in active early rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[125]  Kim Henriksen,et al.  Transforming Growth Factor-β Controls Human Osteoclastogenesis through the p38 MAPK and Regulation of RANK Expression* , 2003, Journal of Biological Chemistry.

[126]  D. Eyre,et al.  The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. , 2003, Arthritis and rheumatism.

[127]  Alexander Fraser,et al.  Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. , 2003, Arthritis and rheumatism.

[128]  J. Delaissé,et al.  Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities , 2003, Microscopy research and technique.

[129]  C. Christiansen,et al.  Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. , 2003, Bone.

[130]  M. Karsdal,et al.  The Type I Collagen Fragments ICTP and CTX Reveal Distinct Enzymatic Pathways of Bone Collagen Degradation , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[131]  G. Kolarz,et al.  Serum levels of cartilage oligomeric matrix proteinA predicting factor and a valuable parameter for disease management in rheumatoid arthritis , 2003, Scandinavian journal of rheumatology.

[132]  B. Månsson,et al.  Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept , 2003, Arthritis research & therapy.

[133]  C. Christiansen,et al.  Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index , 2003, Annals of the rheumatic diseases.

[134]  S. van der Linden,et al.  Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. , 2002, Arthritis and rheumatism.

[135]  M. Dougados,et al.  Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. , 2002, Arthritis and rheumatism.

[136]  L. Klareskog,et al.  Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. , 2002, Rheumatology.

[137]  M. Dougados,et al.  Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide , 2002, Annals of the rheumatic diseases.

[138]  R. Coutts,et al.  Development and regulation of osteophyte formation during experimental osteoarthritis. , 2002, Osteoarthritis and cartilage.

[139]  E. Wagner,et al.  HIF-1 mediated upregulation of VEGF and VEGF-R in systemic sclerosis (SSc): Imbalance with angiostatic factors suggests VEGF as a novel option for the treatment of ischemia in patients with SSc , 2002, Annals of the rheumatic diseases.

[140]  R. Gordon,et al.  Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. , 2001, The American journal of pathology.

[141]  B. Dijkmans,et al.  Predictors of radiographic joint damage in patients with early rheumatoid arthritis , 2001, Annals of the rheumatic diseases.

[142]  P. Qvist,et al.  Collagen type II C-telopeptide fragments as an index of cartilage degradation. , 2001, Bone.

[143]  S. Kondo,et al.  Cytokine regulation of cartilage‐derived retinoic acid‐sensitive protein (CD‐RAP) in primary articular chondrocytes: suppression by IL‐1, bfGF, TGFβ and stimulation by IGF‐1 , 2001, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[144]  P. Delmas,et al.  Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation. , 2001, Rheumatology.

[145]  Eric Lejeune,et al.  Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial , 2001, The Lancet.

[146]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[147]  D. Kiel,et al.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.

[148]  P. Sambrook,et al.  Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. , 2000, The Journal of clinical endocrinology and metabolism.

[149]  J. Risteli,et al.  Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. , 2000, Bone.

[150]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[151]  J. Risteli,et al.  Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. , 1999, Anticancer research.

[152]  B. Gelb,et al.  Determination of Bone Markers in Pycnodysostosis: Effects of Cathepsin K Deficiency on Bone Matrix Degradation , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[153]  C. Christiansen,et al.  Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. , 1999, The Journal of clinical endocrinology and metabolism.

[154]  A. Hollander,et al.  Denaturation of type II collagen in articular cartilage in experimental murine arthritis. Evidence for collagen degradation in both reversible and irreversible cartilage damage , 1999, The Journal of pathology.

[155]  J. V. van Meurs,et al.  Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. , 1999, Arthritis and rheumatism.

[156]  G. Stucki,et al.  Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. , 1999, The Journal of rheumatology.

[157]  M. Dougados,et al.  Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. , 1999, The Journal of rheumatology.

[158]  P. Delmas,et al.  Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products. , 1999, Bone.

[159]  B. Michel,et al.  Cartilage Oligomeric Matrix Protein (COMP): Die Rolle eines nichtkollagenen Knorpel-Matrix- Proteins als Marker der Krankheitsaktivität und Gelenkzerstörung bei Patienten mit rheumatoider Arthritis und Arthrose , 1999, Zeitschrift für Rheumatologie.

[160]  C. Christiansen,et al.  Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. , 1999, Bone.

[161]  H. Weinstein,et al.  Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. , 1999, The Journal of clinical investigation.

[162]  G. Burmester,et al.  Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. , 1999, The Journal of rheumatology.

[163]  P. Dieppe,et al.  Evidence for altered synthesis of type II collagen in patients with osteoarthritis. , 1998, The Journal of clinical investigation.

[164]  C. Christiansen,et al.  Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. , 1998, Clinical chemistry.

[165]  E. Thonar,et al.  Characterization of monoclonal antibodies recognizing different fragments of cartilage oligomeric matrix protein in human body fluids. , 1997, Archives of biochemistry and biophysics.

[166]  C. Rorabeck,et al.  Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. , 1997, The Journal of clinical investigation.

[167]  J. Risteli,et al.  Immunoassay for intact amino-terminal propeptide of human type I procollagen. , 1996, Clinical chemistry.

[168]  C. Christiansen,et al.  Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. , 1995, The Journal of clinical endocrinology and metabolism.

[169]  P. Dieppe,et al.  Biological markers in rheumatoid arthritis. , 1994, Seminars in arthritis and rheumatism.

[170]  D. Heinegård,et al.  Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. , 1994, Annals of the rheumatic diseases.

[171]  J. Johansen,et al.  A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. , 1993, British journal of rheumatology.

[172]  D. Eyre,et al.  A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross‐linked N‐telopeptides in urine , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[173]  D. Heinegård,et al.  Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. , 1992, British journal of rheumatology.

[174]  P. Virkkunen,et al.  Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. , 1992, British Journal of Cancer.

[175]  C. Christiansen,et al.  Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. , 1992, The Journal of clinical endocrinology and metabolism.

[176]  J. Risteli,et al.  Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. , 1990, Clinical chemistry.

[177]  T. Oegema,et al.  Biochemical changes in articular cartilage after joint immobilization by casting or external fixation , 1989, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[178]  J. Risteli,et al.  Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. , 1988, Clinical chemistry.

[179]  P. Roughley,et al.  Age-related changes in protein-related epitopes of human articular-cartilage proteoglycans. , 1986, The Biochemical journal.

[180]  T. Glant,et al.  Monoclonal antibodies to different protein-related epitopes of human articular cartilage proteoglycans. , 1986, The Biochemical journal.

[181]  J. Smolen,et al.  Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlle , 2010, Arthritis and rheumatism.

[182]  G. Schett.  Bone formation versus bone resorption in ankylosing spondylitis. , 2009, Advances in experimental medicine and biology.

[183]  Hannu Kautiainen,et al.  Arthritis Research & Therapy , 2009 .

[184]  J. Houwing-Duistermaat,et al.  Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites. The GARP study. , 2007, Osteoarthritis and cartilage.

[185]  P. Delmas,et al.  Development and clinical application in arthritis of a new immunoassay for serum type IIA procollagen NH2 propeptide. , 2004, Methods in molecular medicine.

[186]  A. Hollander,et al.  Immunoassays for collagens in chondrocyte and cartilage explant cultures. , 2004, Methods in molecular medicine.

[187]  Michael J. Green,et al.  Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. , 2003, Rheumatology.

[188]  Yu. Pogoreltsev,et al.  The Application , 2020, How to Succeed in the Academic Clinical Interview.

[189]  A. Kerin,et al.  Molecular basis of osteoarthritis: biomechanical aspects , 2002, Cellular and Molecular Life Sciences CMLS.

[190]  E. Wagner,et al.  Osteoclasts are essential for TNF-alpha-mediated joint destruction. , 2002, The Journal of clinical investigation.

[191]  A. Yee,et al.  Structure and function of aggrecan , 2002, Cell Research.

[192]  I. Otterness,et al.  Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA. , 2001, Journal of immunological methods.

[193]  T. Gerber,et al.  [Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis]. , 1999, Zeitschrift fur Rheumatologie.

[194]  R. Moskowitz,et al.  Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation. , 1999, Arthritis and rheumatism.

[195]  G. Müller,et al.  COMP (cartilage oligomeric matrix protein) is synthesized in ligament, tendon, meniscus, and articular cartilage. , 1998, Connective tissue research.